|
Date: Monday January 09, 2012
 ORIGINAL ARTICLE
| RELATED PAGE IN CANCERQUEST
|
|
About one in three breast cancer survivors suffers from fatigue. A recent study shows that yoga may help with this problem. Thirty-one breast cancer survivors were divided into two groups, one group received health education and the other participated in yoga two times per week. Women in the yoga group reported reduced fatigue and more 'vigor' after three months of yoga.
|
|
Date: Monday January 09, 2012
ORIGINAL ARTICLE
| RELATED PAGE IN CANCERQUEST
|
|
One of the major problems with the majority of current cancer treatments is that they affect both normal and cancer cells, leading to many unpleasant or even dangerous side effects. A Norweigian company has developed a technology that can reduce or eliminate this problem. The system uses lasers to activate cancer drugs. Because the light can be directed very precisely, the drugs are not activated in normal cells. To make this work, patients would take a chemical that reacts to the laser light (Amphinex®) and an inactive form of the cancer drug. Both of these are taken into all cells. When the laser light hits the target cells, the cancer drug is activated. The method results in sparing of normal cells and a dramatic increase in the potency of the cancer drugs.
|
|
Date: Monday January 09, 2012
ORIGINAL ARTICLE
| RELATED PAGE IN CANCERQUEST
|
|
Scientists from Florida and Canada have teamed up to develop a new tool for watching how cancer drugs affect their targets. The researchers linked drugs to tiny structures known as quantum dots (Qdots). When the drug-Qdot combination enters the cancer cells, the Qdots give off a reddish color, allowing them to be easily detected. The research should speed up the testing of new cancer drugs and allow tracking of drug activity over time.
|
|
Date: Thursday January 05, 2012
ORIGINAL ARTICLE
| RELATED PAGE IN CANCERQUEST
|
|
A chemical naturally formed from Omega-3 fish oil, ¿12-prostaglandin J3, has been shown to cure mice with chronic myelogenous leukemia (CML). The chemical was first identified as a possible drug by a computer analysis. Researchers gave the drug to mice with CML and the results were striking. The mice were cured, with no evidence of disease or relapses. The chemical seems to kill the CML stem cells, the cells at the root of the disease. Studies in humans are planned.
|
|
Date: Thursday January 05, 2012
ORIGINAL ARTICLE
| RELATED PAGE IN CANCERQUEST
|
|
The HER2 protein is serves as an receiver/transmitter on the surface of cells. Signals from HER2 cause cells to divide. Some cancers (including breast cancer) can have too much HER2 on their surface. Treatments, like Herceptin®, block some of these cancer cells but not all HER2 over-expressing cancers respond to the treatments.
To help determine which cancers are likely to respond to treatmens like Herceptin® researchers have turned to using light. When the right light is directed at the cancer cells, those that are being affected by the treatment emit a different color than those that are resistant to the treatment. If this method is able to work inside patients, those that would not respond to a particular treatment can be quickly identified and treated differently.
|
Print
Email Page
